Loading company…
Roca Therapeutics develops small-molecule treatments for severe disorders.
Founded in France in 2021, Roca Therapeutics discovers and develops small molecules for severe, life-threatening disorders. Its programs include RCT001 for metastatic uveal melanoma and RCT002 for neovascular complications after proton therapy. In September 2022, the company raised Seed funding from 3B Future Health Fund and SATT Sud-Est.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in